MBX Biosciences, Inc. MBX
53.41 USD -0.01 (-0.02%)
Regular-session close
54.99 +1.58 +2.96%
After hours · Nov 19, 5:14 PM ET
52.44 Day range 55.85
26.00 52-week range 72.64
- YTD
- +69.34%
- 1 year
- +95.00%
News
benzinga.com This Kimball Electronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage on KE, MBX, ENSC, DORM and AGLT, issuing mostly Buy/positive ratings with new price targets.benzinga.com HC Wainwright & Co. Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $90 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $90.
globenewswire.com MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for…
accessnewswire.com Microbix Attending & Presenting at IPVS 2026 Presenting Results of Novel Product for Validation & QC of HPV Assays MISSISSAUGA, ON / ACCESS Newswire / October 19, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life…
globenewswire.com MBX Biosciences to Participate in Upcoming November Investor Conferences CARMEL, Ind. and BURLINGTON, Mass.
defenseworld.net MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy? Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $55.93 and last traded at $55.84. 88,613 shares were traded during…
defenseworld.net MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE Bank of America Corp DE bought a new position in MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
seekingalpha.com MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy…
seekingalpha.com MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
fool.com Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
globenewswire.com MBX Biosciences to Participate in Upcoming Investor Conferences CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and…
globenewswire.com MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer CARMEL, Ind. and BURLINGTON, Mass.
defenseworld.net Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBX Jupiter Topco LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
globenewswire.com MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
accessnewswire.com Microbix Reports Results for Q3 Fiscal 2026 Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator,…
defenseworld.net MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00.…
defenseworld.net MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $66.66 and last traded at $61.10, with a volume of…
defenseworld.net Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare…
globenewswire.com MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and…
seekingalpha.com MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy) I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables…
seekingalpha.com MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
